What is Single Cell Technology?
Single Cell Technology operates at the intersection of advanced bioinformatics and therapeutic development. The company is the architect of the AbTheneum Antibody Discovery Platform, a sophisticated technological framework designed to streamline the identification of actionable leads. By capturing comprehensive datasets, the platform effectively mitigates the traditional bottlenecks associated with antibody development. This methodology allows for a rapid, high-fidelity discovery process, providing pharmaceutical partners with a distinct advantage when navigating complex therapeutic campaigns. The firm's commitment to integrating engineering precision with biological insight positions it as a critical player in the next generation of drug discovery infrastructure.
How much funding has Single Cell Technology raised?
Single Cell Technology has raised a total of $5.1M across 2 funding rounds:
Private Equity
$5M
Debt
$91K
Private Equity (2018): $5M with participation from ImmunoPrecise Antibodies Ltd
Debt (2021): $91K led by PPP
Key Investors in Single Cell Technology
ImmunoPrecise Antibodies Ltd
A full-service therapeutic antibody discovery organization that provides comprehensive solutions for the biopharmaceutical industry.
PPP
Public-Private Partnership
What's next for Single Cell Technology?
With the recent influx of capital, Single Cell Technology is poised to scale its operational capacity and enhance its AbTheneum platform capabilities. The strategic focus will likely shift toward expanding its client base and refining its lead-generation algorithms to address increasingly difficult therapeutic targets. As the company transitions into this growth phase, the emphasis will remain on maintaining the high-quality output that has defined its early success. Future milestones will likely involve deeper integration into global pharmaceutical pipelines, where the demand for rapid, data-driven antibody discovery remains at an all-time high. The firm is effectively transitioning from a specialized research entity into a scalable enterprise-level solution provider.
See full Single Cell Technology company page
